Universal everolimus for malignant neuroendocrine tumours?
Mené sur 302 patients atteints d'une tumeur neuro-endocrine avancée du poumon ou de l'appareil digestif, cet essai randomisé international de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'évérolimus
Neuroendocrine neoplasms are a heterogeneous group of malignant tumours which vary in localisation, clinical presentation, tumour biology, and prognosis. The tumours derive from the diffuse neuroendocrine cell system, which is spread all over the body. The main tissues affected are thymus, lungs, gastrointestinal tract, and pancreas. Some tumours present clinical syndromes related to peptide and amine production with clinical syndromes like gastrinoma, insulinoma, VIPoma, and glucagonoma syndromes, and the carcinoid syndrome related to serotonin and tachykinin production from small intestinal neuroendocrine tumours (carcinoids).
The Lancet , commentaire, 2014